Zhejiang Orient Gene Biotech Co., Ltd (SHA:688298)
China flag China · Delayed Price · Currency is CNY
17.64
-1.16 (-6.17%)
Nov 13, 2026, 3:00 PM CST

SHA:688298 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-658.27-573.6-529.02-397.582,0684,920
Depreciation & Amortization
192.99193.96206.38165.4986.5637.31
Other Amortization
26.325.3321.99188.512.27
Loss (Gain) From Sale of Assets
-1.75-1.75-0.990.180.01-0.01
Asset Writedown & Restructuring Costs
173.72173.7281.7563.86366.580.05
Loss (Gain) From Sale of Investments
-7.08-7.08-24.6-48.85-7.66-11.22
Provision & Write-off of Bad Debts
4.454.4530.130.17-6.4432.55
Other Operating Activities
174.1820.35-8.2496.57378.84109.18
Change in Accounts Receivable
-71.21-71.21-109.37210.28825.4-692.05
Change in Inventory
-26.63-26.631.91-86.23-775.13-98.7
Change in Accounts Payable
56.456.4-11.52-1,670172.34928.52
Change in Other Net Operating Assets
--15.78---
Operating Cash Flow
-124.75-193.9-348.33-1,6462,9965,204
Operating Cash Flow Growth
-----42.43%190.67%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-269.32-307.67-924.09-996.05-1,052-507.87
Sale of Property, Plant & Equipment
2.482.627.510.812.581.79
Cash Acquisitions
---320.76-78.52-184.87-43.71
Investment in Securities
-156.7749.54678.2681.54-1,076228.15
Other Investing Activities
887.65833.12-111.06-1,126-65.22-
Investing Cash Flow
464.04577.6-670.15-2,118-2,376-321.64

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-384300.7577250-
Total Debt Issued
324.16384300.7577250-
Long-Term Debt Repaid
--526.77-459.27-331.82-6.21-6.97
Lease Payments
-16.71-16.71-27.57-13.32-6.21-6.97
Total Debt Repaid
-153.31-526.77-459.27-331.82-6.21-6.97
Net Debt Issued (Repaid)
170.85-142.77-158.52440.1843.79-6.97
Repurchase of Common Stock
-49.99-49.99-276.95---
Common Dividends Paid
-6.5-6.71-16.63-351.14-742.04-504.67
Other Financing Activities
16.57-34.410.36-39.51-2.47
Financing Cash Flow
130.92-233.88-451.7449.54-698.25-509.17

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-81.06-24.4151.8985.85536.65-75.44
Net Cash Flow
389.16125.41-1,418-3,628458.624,298

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-394.07-501.57-1,272-2,6421,9444,696
Free Cash Flow Growth
-----58.60%182.32%
Free Cash Flow Margin
-39.68%-52.94%-153.69%-322.09%22.17%46.18%
Free Cash Flow Per Share
-2.06-2.61-6.47-13.099.6423.29
Levered Free Cash Flow
-389.28-463.51-1,255-2,3791,5133,361
Unlevered Free Cash Flow
-387.77-457.32-1,243-2,3681,5173,362
Free Cash Flow After Leases
-410.78-518.28-1,300-2,6551,9384,689

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Income Tax Paid
--5.48-13.59-24.311,112260.08
Change in Working Capital
-29.27-29.27-125.68-1,573101.82113.54